Compile Data Set for Download or QSAR
maximum 50k data
Found 90 Enz. Inhib. hit(s) with all data for entry = 417
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241685(US9409915, 89 | US9718820, Compound 89)
Affinity DataIC50:  0.530nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241633(US9409915, 16 | US9718820, Compound 16)
Affinity DataIC50:  0.590nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241638(US9409915, 21 | US9718820, Compound 21)
Affinity DataIC50:  0.690nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241686(US9409915, 90 | US9718820, Compound 90)
Affinity DataIC50:  0.730nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241636(US9409915, 19 | US9718820, Compound 19)
Affinity DataIC50:  0.840nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241637(US9409915, 20 | US9718820, Compound 20)
Affinity DataIC50:  0.950nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241620(US9409915, 59 | US9718820, Compound 59A)
Affinity DataIC50:  1.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241631(US9409915, 14 | US9718820, Compound 14)
Affinity DataIC50:  1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241689(US9409915, 93 | US9718820, Compound 93)
Affinity DataIC50:  1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267422(3-tert-Butyl-1-methyl-5-[4-piperidin-1-yl-6-(2-tri...)
Affinity DataIC50:  1.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241606(US9409915, 57 | US9718820, Compound 57)
Affinity DataIC50:  1.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241634(US9409915, 17 | US9718820, Compound 17)
Affinity DataIC50:  1.70nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241680(US9409915, 83 | US9718820, Compound 83)
Affinity DataIC50:  1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241632(US9409915, 15 | US9718820, Compound 15)
Affinity DataIC50:  1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241681(US9409915, 84 | US9718820, Compound 84)
Affinity DataIC50:  1.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241666(US9409915, 58 | US9718820, Compound 58)
Affinity DataIC50:  2nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241688(US9409915, 92 | US9718820, Compound 92)
Affinity DataIC50:  2.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241667(US9409915, 63 | US9718820, Compound 63A)
Affinity DataIC50:  3.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267459(3-tert-Butyl-1-methyl-5-[4-morpholin-4-yl-6-(2-tri...)
Affinity DataIC50:  3.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241619(US9409915, 11 | US9718820, Compound 11)
Affinity DataIC50:  3.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241687(US9409915, 91 | US9718820, Compound 91)
Affinity DataIC50:  3.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241663(US9409915, 54 | US9718820, Compound 54)
Affinity DataIC50:  4.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241691(US9409915, 97 | US9718820, Compound 97)
Affinity DataIC50:  4.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267455(2-(5-tert-Butyl-4-chloro-2-methyl-2H-pyrazol-3-yl)...)
Affinity DataIC50:  5.30nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241609(US9409915, 103 | US9718820, Compound 103)
Affinity DataIC50:  5.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267409(2-(5-tert-Butyl-4-chloro-2-methyl-2H-pyrazol-3-yl)...)
Affinity DataIC50:  5.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241675(US9409915, 76 | US9718820, Compound 76)
Affinity DataIC50:  5.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267408(2-(3-tert-Butyl-isoxazol-5-yl)-4-methoxy-6-(2-trif...)
Affinity DataIC50:  6nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241659(US9409915, 49 | US9718820, Compound 49)
Affinity DataIC50:  6.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241670(US9409915, 66 | US9718820, Compound 66)
Affinity DataIC50:  6.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241640(US9409915, 24 | US9718820, Compound 24)
Affinity DataIC50:  7.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267432(2-(5-tert-Butyl-4-chloro-2-methyl-2H-pyrazol-3-yl)...)
Affinity DataIC50:  7.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267418(2-(2-methyl-6,6-spirocyclohexyl-2,4,5,6-tetrahydro...)
Affinity DataIC50:  8.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241612(US9409915, 71 | US9718820, Compound 71)
Affinity DataIC50:  8.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241629(US9409915, 12 | US9718820, Compound 12)
Affinity DataIC50:  11nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241618(US9409915, 28 | US9718820, Compound 28)
Affinity DataIC50:  11nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267425(2-(5-tert-Butyl-4-chloro-2-methyl-2H-pyrazol-3-yl)...)
Affinity DataIC50:  12nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM264730(2-(5-tert-Butyl-4-chloro-2-methyl-2H-pyrazol-3-yl)...)
Affinity DataIC50:  13nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241692(US9409915, 98 | US9718820, Compound 98)
Affinity DataIC50:  14nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241668(US9409915, 64 | US9718820, Compound 64)
Affinity DataIC50:  14nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241597(US9409915, 5 | US9718820, Compound 5)
Affinity DataIC50:  16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241677(US9409915, 78 | US9718820, Compound 78)
Affinity DataIC50:  16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241628(US9409915, 10 | US9718820, Compound 10)
Affinity DataIC50:  16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241598(US9409915, 3 | US9718820, Compound 3)
Affinity DataIC50:  17nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241616(US9409915, 31 | US9718820, Compound 31)
Affinity DataIC50:  18nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241675(US9409915, 76 | US9718820, Compound 76)
Affinity DataIC50:  19nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241637(US9409915, 20 | US9718820, Compound 20)
Affinity DataIC50:  19nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241610(US9409915, 79 | US9718820, Compound 80)
Affinity DataIC50:  20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241676(US9409915, 77 | US9718820, Compound 77)
Affinity DataIC50:  20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM267439(2-(5-tert-Butyl-4-chloro-2-methyl-2H-pyrazol-3-yl)...)
Affinity DataIC50:  22nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: